VEGFA and cancer: Although recently, targeted molecular therapeutics such as trastuzumab directed against the HER2 receptor and bevacizumab against vascular endothelial growth factor (VEGF)-A have been developed for and used successfully to treat certain cancers, there are none with more than limited efficacy in GC [22], suggesting the urgent need to identify new molecular targets for this disease [5], [23].